These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 18086726

  • 1. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
    Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, López-Longo J, Figueroa M, Belzunegui J, Mola EM, Bonilla G.
    Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
    [Abstract] [Full Text] [Related]

  • 2. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
    Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, Boesen M, Danneskiold-Samsøe B, Torp-Pedersen S.
    Scand J Rheumatol; 2006 May; 35(5):341-5. PubMed ID: 17062431
    [Abstract] [Full Text] [Related]

  • 3. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

  • 4. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial.
    Dougados M, Combe B, Braun J, Landewé R, Sibilia J, Cantagrel A, Feydy A, van der Heijde D, Leblanc V, Logeart I.
    Ann Rheum Dis; 2010 Aug 02; 69(8):1430-5. PubMed ID: 20511606
    [Abstract] [Full Text] [Related]

  • 5. Etanercept plus standard therapy for Wegener's granulomatosis.
    Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.
    N Engl J Med; 2005 Jan 27; 352(4):351-61. PubMed ID: 15673801
    [Abstract] [Full Text] [Related]

  • 6. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial.
    Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ.
    Arthritis Rheum; 2006 Oct 27; 54(10):3310-8. PubMed ID: 17009270
    [Abstract] [Full Text] [Related]

  • 7. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
    Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR.
    Arthritis Rheum; 2004 Jul 27; 50(7):2240-5. PubMed ID: 15248223
    [Abstract] [Full Text] [Related]

  • 8. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.
    Ann Rheum Dis; 2005 Nov 27; 64(11):1557-62. PubMed ID: 15843448
    [Abstract] [Full Text] [Related]

  • 9. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.
    Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C.
    Arthritis Rheum; 2007 Dec 15; 57(8):1514-9. PubMed ID: 18050171
    [Abstract] [Full Text] [Related]

  • 10. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.
    Chevalet P, Barrier JH, Pottier P, Magadur-Joly G, Pottier MA, Hamidou M, Planchon B, El Kouri D, Connan L, Dupond JL, De Wazieres B, Dien G, Duhamel E, Grosbois B, Jego P, Le Strat A, Capdeville J, Letellier P, Agron L.
    J Rheumatol; 2000 Jun 15; 27(6):1484-91. PubMed ID: 10852275
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.
    Ann Rheum Dis; 2008 Mar 15; 67(3):346-52. PubMed ID: 17967833
    [Abstract] [Full Text] [Related]

  • 12. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 13. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov 15; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 14. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, Zitnik R, van de Kerkhof PC, Melvin L, Etanercept Psoriasis Study Group.
    Br J Dermatol; 2005 Jun 15; 152(6):1304-12. PubMed ID: 15948997
    [Abstract] [Full Text] [Related]

  • 15. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
    Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, Kerr DR, Tsuji W, Baumgartner SW.
    Rheumatology (Oxford); 2007 Jul 15; 46(7):1122-5. PubMed ID: 17470434
    [Abstract] [Full Text] [Related]

  • 16. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC, Segaert S, Lahfa M, Luger TA, Karolyi Z, Kaszuba A, Leigheb G, Camacho FM, Forsea D, Zang C, Boussuge MP, Paolozzi L, Wajdula J.
    Br J Dermatol; 2008 Nov 15; 159(5):1177-85. PubMed ID: 18673365
    [Abstract] [Full Text] [Related]

  • 17. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
    Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KM, Soori GS, Wender DB, Fitch TR, Novotny PJ, Loprinzi CL.
    Cancer; 2007 Sep 15; 110(6):1396-403. PubMed ID: 17674351
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.
    Arch Dermatol; 2007 Jun 15; 143(6):719-26. PubMed ID: 17576937
    [Abstract] [Full Text] [Related]

  • 19. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR.
    J Am Acad Dermatol; 2007 Apr 15; 56(4):598-603. PubMed ID: 17113190
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up.
    Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS.
    Ann Rheum Dis; 2008 Nov 15; 67(11):1567-9. PubMed ID: 18677012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.